LRRC15 and neoplasm: In summary, we propose targeting LRRC15+ cells with [177Lu]Lu-DUNP19 as a novel theranostic strategy that provides sustained tumor control across models of LRRC15+ disease, improves survival, and reprograms the transcriptomic landscape of pro-tumorigenic and immunosuppressive mechanisms within the TME, all with minimal side effects.